What question did this study set out to answer?

The study aims to develop effective IKZF2 degraders to counteract immunosuppressive Tregs in cancer.

Discovery of Highly Potent and Selective IKZF2 Degraders for Cancer Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Novel IKZF2 degraders enhance anti-tumor immunity in cancer, suggesting new therapy options.

The study aims to develop effective IKZF2 degraders to counteract immunosuppressive Tregs in cancer.
Designed and synthesized phthalazinone-based glutarimide derivatives.
Identified compound 25 as a selective IKZF2 degrader.
Evaluated IKZF2 degradation and its effects on IL-2 production in vitro and in vivo.
Assessed tumor growth suppression with compound 25 and anti-PD-1 antibody therapy.
Compound 25 induced robust IKZF2 degradation with DC50 of 1.78 nM and Dmax of 93.2%.
Demonstrated enhanced IL-2 production and reduced Treg activity.
Oral administration of compound 25 led to sustained IKZF2 degradation in mouse spleen and thymus.
As a standalone treatment, compound 25 significantly inhibited B16F tumor growth.
Combination with anti-PD-1 antibody showed marked synergistic effects.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark